Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine plus Furmonertinib as first-line therapy in refractory EGFR-mutated NSCLC
ChiCTR2500111096Phase 4Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vinorelbine and furmonertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shanghai Chest Hospital. Primary endpoint: progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
vinorelbinefurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111096.